- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Severe hypocalcaemia following denosumab and iron infusion. (Pubmed Central) - Aug 22, 2022
We recommend a systematic review that can include more studies in this field to acquire more definitive results regarding this topic. No abstract available
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Review, Journal: Bone Disease in Multiple Myeloma: Biologic and Clinical Implications. (Pubmed Central) - Aug 22, 2022
The use of osteoclast inhibitory therapies with bisphosphonates, such as zoledronic acid and the RANKL inhibitor denosumab, have been shown to delay and lower the risk of SREs, as well as the need for surgery or radiation therapy to treat severe bone complications. This review outlines our current understanding of the molecular underpinnings of bone disease, available therapeutic options, and highlights recent advances in the management of MM-related bone disease.
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo, Evenity (romosozumab) / Astellas, Amgen, UCB
Review, Journal: Extensive Expertise in Endocrinology: Osteoporosis Management. (Pubmed Central) - Aug 21, 2022
Romosozumab is unique in that it has both activities...Denosumab is a further potent anti-resorptive agent given as 6-monthly s.c. injections...25-hydroxyvitamin D levels should be maintained above 30 nmol/L, using supplements if sunlight exposure is limited. Calcium intake has little effect on bone density and fracture risk but should be maintained above 500 mg/day using dietary sources.
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion: Denosumab and Osteoporotic Vertebral Compression Fracture (clinicaltrials.gov) - Aug 19, 2022
P2/3, N=90, Completed,
Calcium intake has little effect on bone density and fracture risk but should be maintained above 500 mg/day using dietary sources. Recruiting --> Completed
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Bone Mass Gains After One Denosumab Injection Followed by Zoledronate. (Pubmed Central) - Aug 18, 2022
A single denosumab injection followed by zoledronate led to a remarkable gain of BMD at the lumbar spine and hip within a short time. This observation could help to identify a new short treatment sequence for patients with osteoporosis.
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Biomarker, Observational data, Journal: Efficacy of Denosumab for Osteoporosis in Patients with Rheumatic Diseases. (Pubmed Central) - Aug 17, 2022
A multivariate analysis of factors related to BMD changes highlighted a young age, low prednisolone dosage, and reduction in NTx. Conclusions Denosumab increases the BMD to combat osteoporosis in rheumatic disease patients, and potential predictors of a better response to denosumab include a young age, reduction in bone turnover markers, and low-dose glucocorticoid use.
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo, Evenity (romosozumab) / Astellas, Amgen, UCB
Review, Journal: Interest of Bone Histomorphometry in Bone Pathophysiology Investigation: Foundation, Present, and Future. (Pubmed Central) - Aug 17, 2022
Bone histomorphometric studies allow us to understand the mechanism of coupling between formation and resorption and to evaluate the respective role of bone modeling and remodeling. The adaptation of new image analysis techniques will help bone biopsy analysis in the future.
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Giant cell tumour of the bone under treatment with Denosumab () - Aug 16, 2022 - Abstract #ECP2022ECP_598;
Denosumab inhibits RANKL and thus reduces bone lysis, which helps control the disease. This drug induces morphological changes in bone histology that ought to be recognized in order to make the differential diagnosis with its mimics, which include malignant lesions.
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Review, Journal: Managements of osteoporotic vertebral compression fractures: A narrative review. (Pubmed Central) - Aug 13, 2022
Bisphosphonates and denosumab are the first-line treatments for osteoporosis...Posterior decompression and fixation or Anterior decompression and reconstruction may be required if neurological deficits are present. The detailed pathogenesis and related targeted treatment options still need to be developed for better clinical outcomes.
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Trends in osteoporosis care patterns during the COVID-19 pandemic in Alberta, Canada. (Pubmed Central) - Aug 11, 2022
Osteoporosis has a known substantial care and management disparity, which has been classified as a crisis. The COVID-19 pandemic created additional burden on osteoporosis patient care with healthcare encounters, physician visits, diagnostic and laboratory tests, and treatment initiations all declining during the initial pandemic period, relative to previous years.
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Review, Journal: Update on aneurysmal bone cyst: pathophysiology, histology, imaging and treatment. (Pubmed Central) - Aug 11, 2022
The main differential diagnosis of an ABC in the pediatric population is unicameral bone cyst (UBC) and telangiectatic osteosarcoma, therefore a biopsy is recommended before treatment. The therapeutic options of ABC range from curettage with or without adjuncts such as phenol, liquid nitrogen, argon laser and bone grafting or bone substitutes to more recently employed alternatives such as image-guided sclerotherapy with various sclerosing agents and monoclonal antibodies (e.g., Denosumab).
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Clinical data, Journal: Tips and Tricks and Clinical Outcome of Cryopreserved Human Amniotic Membrane Application for the Management of Medication-Related Osteonecrosis of the Jaw (MRONJ): A Pilot Study. (Pubmed Central) - Aug 10, 2022
Medication-related osteonecrosis of the jaw (MRONJ) is a complication of certain pharmacological treatments such as bisphosphonates, denosumab, and angiogenesis inhibitors...One patient did not attend his follow-up radiological examination. For the first time, this prospective pilot study extensively illustrates both the handling and surgical application of hAM in MRONJ, its possible association with a collagen sponge scaffold, its outcome at the site, the application of multiple hAM patches at the same time, and its reapplication.
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Review, Journal: Medication-Related Osteonecrosis of the Jaw (MRONJ): A Review of Pathophysiology, Risk Factors, Preventive Measures and Treatment Strategies. (Pubmed Central) - Aug 10, 2022
Medication-related osteonecrosis of the jaw (MRONJ) is a major problem that can occur in people taking certain medications such bisphosphonates and denosumab...The objectives of this literature review are to recognize the main diagnostic principles and risk factors and to review the pathophysiology, protective procedures and treatment modalities related to MRONJ. The following topics are covered in the review: epidemiology, diagnostic criteria, risk factors, pathogenesis and mechanism, MRONJ staging and symptoms, clinical and radiographic findings, treatment strategies, prevention and drug holiday.
- |||||||||| Prolia (denosumab) / Amgen
Enrollment closed, Trial primary completion date: Denosumab for Smoldering Multiple Myeloma (clinicaltrials.gov) - Aug 10, 2022
P2, N=20, Active, not recruiting,
The following topics are covered in the review: epidemiology, diagnostic criteria, risk factors, pathogenesis and mechanism, MRONJ staging and symptoms, clinical and radiographic findings, treatment strategies, prevention and drug holiday. Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2022 --> Aug 2021
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Giant Cell Tumor of Bone Versus Tenosynovial Giant Cell Tumor - Similarities and Differences. (Pubmed Central) - Aug 6, 2022
Systemically, it can be treated with bisphosphonates and denosumab or radiotherapy.TGCT is a rare, slowly progressing tumor of synovial tissue, affecting the joint, tendon sheath or bursa, mostly seen in middle-aged patients...Localised TGCT is mostly treated with marginal surgical resection, while diffuse TGCT is optimally treated with total synovectomy and is more difficult to remove. Additionally, radiotherapy, intraarticular injection of radioactive isotopes, anti-TNF-α antibodies and targeted medications may be used.
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Successful limb salvage in progressive proximal tibia osteosarcoma following denosumab chemotherapy: A case report. (Pubmed Central) - Aug 6, 2022
Treatment with receptor activator of nuclear factor-ĸB ligand inhibitor denosumab combined with standard chemotherapy is effective for advanced OS progressing after chemotherapy. We recommend denosumab therapy for successful limb salvage in patients with high-grade OS associated with osteolytic bone destruction and refractory to preoperative neoadjuvant chemotherapy.
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo, Ocaliva (obeticholic acid) / Intercept, Invokana (canagliflozin) / J&J, Daiichi Sankyo, Mitsubishi Tanabe
Review, Journal: Nonalcoholic fatty liver disease and osteoporosis: a potential association with therapeutic implications. (Pubmed Central) - Aug 5, 2022
If an association between NAFLD and osteoporosis is established, a medication that could target both diseases would be a great advancement. This review summarized the main experimental and clinical evidence on the potential association between NAFLD and osteoporosis and focused on treatment considerations derived from this potential association.
- |||||||||| MB09 (denosumab biosimilar) / Grupo Insud, Amneal, Korea Kolmar
Enrollment closed: A Study Comparing the Pharmacokinetic Similarity of MB09 and EU/US-Sourced Xgeva (clinicaltrials.gov) - Aug 4, 2022
P1, N=255, Active, not recruiting,
This review summarized the main experimental and clinical evidence on the potential association between NAFLD and osteoporosis and focused on treatment considerations derived from this potential association. Recruiting --> Active, not recruiting
- |||||||||| AVT03 (denosumab biosimilar) / Alvotech, Dr. Reddy's
Enrollment open, Phase classification: AVT03 With Prolia in Healthy Male Subjects (clinicaltrials.gov) - Aug 3, 2022
P=N/A, N=206, Recruiting,
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Phase classification: P1 --> PN/A
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Review, Journal: Medication-related osteonecrosis of the jaw: An update. (Pubmed Central) - Aug 3, 2022
Antiresorptive medications, such as bisphosphonates and denosumab, are an important class of medication used to treat a wide range of diseases from osteoporosis to multiple myeloma...published a paper on bisphosphonate-related osteonecrosis of the jaw; however, there have many changes since then. This paper aims to provide a succinct update on those changes.
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Clinical data, Journal, Real-world evidence: Clinical outcomes of follicular tumor of uncertain malignant potential of the thyroid: real-world data. (Pubmed Central) - Jul 31, 2022
To date, five patients (1%) have shown distant recurrence during postoperative follow-up and underwent various treatments such as radioactive iodine therapy, orthopedic surgery, and denosumab injection...Our findings suggest that FT-UMP is generally an indolent disease, but some patients show distant recurrence. Physicians should carefully follow patients, although it remains unknown how long they should be observed after surgery.
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Review, Journal: Interventions for managing medication-related osteonecrosis of the jaw. (Pubmed Central) - Jul 30, 2022
Medication-related osteonecrosis of the jaw (MRONJ) is a severe adverse reaction experienced by some individuals to certain medicines commonly used in the treatment of cancer and osteoporosis (e.g. bisphosphonates, denosumab, and antiangiogenic agents), and involves the progressive destruction of bone in the mandible or maxilla...One RCT compared standard care with regular dental examinations at three-month intervals and preventive treatments (including antibiotics before dental extractions and the use of techniques for wound closure that avoid exposure and contamination of bone) in men with metastatic prostate cancer treated with zoledronic acid...Another RCT that compared autofluorescence- with tetracycline fluorescence-guided sequestrectomy for the surgical treatment of MRONJ found no significant difference (at one-year follow-up: RR 1.05, 95% CI 0.86 to 1.30, 34 participants). Three RCTs investigated the effect of growth factors and autologous platelet concentrates on healing rates of MRONJ: platelet-rich fibrin after bone surgery versus surgery alone (RR 1.05, 95% CI 0.90 to 1.22, 47 participants), bone morphogenetic protein-2 together with platelet-rich fibrin versus platelet-rich fibrin alone (RR 1.10, 95% CI 0.94 to 1.29, 55 participants), and concentrated growth factor and primary wound closure versus primary wound closure only (RR 1.38, 95% CI 0.81 to 2.34, 28 participants)...Although some interventions suggested a potential large effect, the studies were underpowered to show statistical significance, and replication of the results in larger studies is pending. Treatment of medication-related osteonecrosis of the jaw The available evidence is insufficient to either claim or refute a benefit, in addition to standard care, of any of the interventions studied for the treatment of MRONJ.
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Review, Journal: Timing of osteoporosis therapies following fracture: the current status. (Pubmed Central) - Jul 30, 2022
To summarize, among the commonly used anti-osteoporosis agents, both bisphosphonates and teriparatide are safe to be initiated in the early acute post-fracture period. Moreover, teriparatide has shown some evidence in favor of reducing fracture healing time.
|
